Multi-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors

Abstract

Objectives The aim of this study was to analyze the effect of the multimodality treatment on survival in sinonasal minor salivary gland tumors.

Methods Adult clinical American Joint Committee on Cancer (AJCC) tumor (T) 1-4a staged cases of sinonasal minor salivary gland tumors were isolated from the National Cancer Database (2004–2014). Multivariate regressions were performed to analyze the effect of multimodality treatment. A subset analysis was also performed in patients with positive margins following surgical management.

Results We identified 556 cases, of which 293 (52.7%) patients were treated with surgery and radiotherapy (RT), 160 (28.8%) were treated with surgery alone, and 52 (9.4%) were treated with surgery and chemoradiotherapy (CRT). No patients were treated with chemotherapy alone. With surgery and CRT as a reference, the only treatment modality associated with decreased survival was RT alone (hazard ratio [HR]: 3.213 [95% confidence interval (CI): 1.578–6.543]; p = 0.001). Within a subset analysis of patients with positive margins, surgery was associated with decreased survival (HR: 2.021 [95% CI: 1.401–3.925]; p = 0.038), but not triple modality therapy (HR: 1.700 [95% CI: 0.798–3.662]) when compared with surgery with RT.

Conclusion The most common treatment was surgery and RT, consistent with National Comprehensive Cancer Network (NCCN) guidelines which recommends chemotherapy (CT) only in the most concerning cases. However, we found no difference in survival among most treatment modalities when compared with triple modality therapy, with the exception of RT alone. Although margins were prognostic within these cancers, we found no evidence that adjuvant CRT provides any survival benefit over surgery and RT, though surgery alone was associated with decreased survival.

Keywords

sinonasal minor salivary gland tumors - NCDB - multimodality treatment - sinonasal tumors - outcomes

Conference

Accepted for podium presentation at 29th Annual North American Skull Base Society Meeting.

• References

• 1 Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006; 24 (17) 2673-2678
• 2 Spiro RH, Koss LG, Hajdu SI, Strong EW. Tumors of minor salivary origin. A clinicopathologic study of 492 cases. Cancer 1973; 31 (01) 117-129
• 3 Lee SY, Shin HA, Rho KJ, Chung HJ, Kim SH, Choi EC. Characteristics, management of the neck, and oncological outcomes of malignant minor salivary gland tumours in the oral and sinonasal regions. Br J Oral Maxillofac Surg 2013; 51 (07) e142-e147
• 4 Dutta R, Dubal PM, Svider PF, Liu JK, Baredes S, Eloy JA. Sinonasal malignancies: A population-based analysis of site-specific incidence and survival. Laryngoscope 2015; 125 (11) 2491-2497
• 5 Wang X, Luo Y, Li M, Yan H, Sun M, Fan T. Management of salivary gland carcinomas - a review. Oncotarget 2017; 8 (03) 3946-3956
• 6 Pantvaidya GH, Vaidya AD, Metgudmath R, Kane SV, D'Cruz AK. Minor salivary gland tumors of the sinonasal region: results of a retrospective analysis with review of literature. Head Neck 2012; 34 (12) 1704-1710
• 7 Youlden DR, Cramb SM, Peters S. , et al. International comparisons of the incidence and mortality of sinonasal cancer. Cancer Epidemiol 2013; 37 (06) 770-779
• 8 NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines). 2018 Available from: https://www.nccn.org/professionals/default.aspx . Accessed August 1, 2018
• 9 Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer DataBase: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008; 15 (03) 683-690
• 10 Li H, Torabi SJ, Yarbrough WG, Mehra S, Osborn HA, Judson B. Association of human papillomavirus status at head and neck carcinoma subsites with overall survival. JAMA Otolaryngol Head Neck Surg 2018; 144 (06) 519-525
• 11 Cheraghlou S, Torabi SJ, Husain ZA. , et al. HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes. Laryngoscope 2019; 129 (03) 684-691
• 12 Kuo P, Torabi SJ, Kraus D, Judson BL. Survival outcomes for induction vs adjuvant chemotherapy in squamous cell carcinoma of the maxillary sinus. Otolaryngol Head Neck Surg 2018 ; (e-pub ahead of print) Doi: 10.1177/0194599818804777
• 13 Kuo P, Manes RP, Schwam ZG, Judson BL. Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma. Otolaryngol Head Neck Surg 2017; 156 (01) 132-136
• 14 Tran L, Sidrys J, Horton D, Sadeghi A, Parker RG. Malignant salivary gland tumors of the paranasal sinuses and nasal cavity. The UCLA experience. Am J Clin Oncol 1989; 12 (05) 387-392
• 15 Michel G, Joubert M, Delemazure AS, Espitalier F, Durand N, Malard O. Adenoid cystic carcinoma of the paranasal sinuses: retrospective series and review of the literature. Eur Ann Otorhinolaryngol Head Neck Dis 2013; 130 (05) 257-262
• 16 Rhee CS, Won TB, Lee CH. , et al. Adenoid cystic carcinoma of the sinonasal tract: treatment results. Laryngoscope 2006; 116 (06) 982-986
• 17 Wiseman SM, Popat SR, Rigual NR. , et al. Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases. Ear Nose Throat J 2002; 81 (08) 510-514 , 516–517
• 18 Le QT, Birdwell S, Terris DJ. , et al. Postoperative irradiation of minor salivary gland malignancies of the head and neck. Radiother Oncol 1999; 52 (02) 165-171
• 19 Bugra Cengiz A, Uyar M, Comert E, Dursun E, Eryilmaz A. Sinonasal tract malignancies: prognostic factors and surgery outcomes. Iran Red Crescent Med J 2013; 15 (12) e14118
• 20 Bignami M, Lepera D, Volpi L. , et al. Sinonasal non-intestinal-type adenocarcinoma: a retrospective review of 22 patients. World Neurosurg 2018; 120: e962-e969
• 21 Manjunath L, Derousseau T, Batra PS. Prognostic value of surgical margins during endoscopic resection of paranasal sinus malignancy. Int Forum Allergy Rhinol 2015; 5 (05) 454-459
• 22 Bossi P, Saba NF, Vermorken JB. , et al. The role of systemic therapy in the management of sinonasal cancer: a critical review. Cancer Treat Rev 2015; 41 (10) 836-843